Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Paul M. Barr(University of Rochester Medical Center), Susan O’Brien(University of California, Irvine), Sandra Dai(AbbVie (United States)), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Talha Munir(Leeds Teaching Hospitals NHS Trust), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Carlos I. Amaya-Chanaga(AbbVie (United States)), Paolo Ghia(Vita-Salute San Raffaele University), Stephen P. Mulligan(Royal North Shore Hospital), John C. Byrd(University of Cincinnati), James P. Dean(AbbVie (United States)), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda)
Cited by 2
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k